J. Mark Sloan MD

Published on 12/10/2024

Abdallah M, Arters F, Patel J, Edwards C, Lerner A, Petrocca F, Dockerty M, Fuller B, Godfrey A, Staron A, Sanchorawala V, Sloan JM, Bertrand K, Szalat R. Febrile neutropenia in patients with Duffy-null-associated neutrophil counts and multiple myeloma or AL amyloidosis. Blood Adv. 2024 Dec 10; 8(23):5935-5938. PMID: 39348709.

Published on 11/26/2024

Sanchorawala V, Barroso B, Shelton A, Goetz E, Mendelson L, Joshi T, Burke N, Sloan JM, Staron A. Defying the odds: 30 years in AL amyloidosis research-recent barriers to clinical trial enrollment. Blood Adv. 2024 Nov 26; 8(22):5826-5828. PMID: 39293090.

Published on 6/1/2023

Gustine JN, Szalat RE, Staron A, Joshi T, Mendelson L, Sloan JM, Sanchorawala V. Light chain amyloidosis associated with Waldenström macroglobulinemia: treatment and survival outcomes. Haematologica. 2023 Jun 01; 108(6):1680-1684. PMID: 36546447.

Published on 5/8/2023

Freydman J, Staron A, Hughes D, Sloan JM. Successful dasatinib therapy in newly diagnosed chronic myeloid leukemia in the setting of short bowel syndrome. J Oncol Pharm Pract. 2023 Sep; 29(6):1489-1493. PMID: 37157792.

Published on 8/12/2022

Hassan H, Verma K, Ferri G, Brauneis D, Quillen K, Sloan JM, Sanchorawala V, Edwards CV. Modified High-Dose versus High-Dose Melphalan Conditioning in Older Patients Undergoing Autologous Stem Cell Transplantation for Immunoglobulin Light Chain Amyloidosis. Transplant Cell Ther. 2022 Nov; 28(11):761.e1-761.e7. PMID: 35970300.

Published on 7/5/2022

Gustine JN, Staron A, Szalat RE, Mendelson LM, Joshi T, Ruberg FL, Siddiqi O, Gopal DM, Edwards CV, Havasi A, Kaku M, Lau KHV, Berk JL, Sloan JM, Sanchorawala V. Predictors of hematologic response and survival with stem cell transplantation in AL amyloidosis: A 25-year longitudinal study. Am J Hematol. 2022 Sep; 97(9):1189-1199. PMID: 35731907.

Published on 3/9/2022

Hughes DM, Henshaw L, Blevins F, Edwards C, Lerner A, Sloan JM, Sanchorawala V. Standard 30-minute Monitoring Time and Less Intensive Pre-medications is Safe in Patients Treated With Subcutaneous Daratumumab for Multiple Myeloma and Light Chain Amyloidosis. Clin Lymphoma Myeloma Leuk. 2022 Aug; 22(8):566-568. PMID: 35367193.

Published on 2/25/2022

Milrod CJ, Mann M, Blevins F, Hughes D, Patel P, Li KY, Lerner A, Sanchorawala V, Sloan JM. Underrepresentation of Black participants and adverse events in clinical trials of lenalidomide for myeloma. Crit Rev Oncol Hematol. 2022 Apr; 172:103644. PMID: 35227897.

Published on 2/2/2022

Gupta VK, El-Jawahri A, Orkev G, Johnson MH, Weinberg J, Goodrich C, Janakiram M, Sloan JM. Impact of Human T Cell Lymphotropic Virus Type 1 and 2 Infection on Survival Following Stem Cell Transplantation. Transplant Cell Ther. 2022 May; 28(5):276.e1-276.e5. PMID: 35123118.

Published on 11/29/2021

Furtado VF, Brauneis D, Weinberg J, Elhassan N, Sloan JM, Sanchorawala V. Early serum free light chain response after high-dose melphalan and stem cell transplantation predicts hematologic response in AL amyloidosis. Bone Marrow Transplant. 2022 02; 57(2):306-308. PMID: 34845368.